SCHEMBL3207372

SCHEMBL3207372

Nc1nc(N)c2ncn([C@H]3C[C@H](O)[C@@H](COP(=O)(O)O)O3)c2n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 2/20 0.72
POLB P06746 2/20 0.65
ENPP1 P22413 3/20 0.59
P2RY1 P47900 3/20 0.59
PDE4D Q08499 2/20 0.58
PDE3A Q14432 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
PNP P00491 1/20 0.58
LMNA P02545 1/20 0.58
TP53 P04637 1/20 0.58
HTT P42858 1/20 0.58
RXFP1 Q9HBX9 1/20 0.58
CA5A P35218 1/20 0.57
DNPH1 O43598 1/20 0.52
PRKAB2 O43741 1/20 0.52
TRPM2 O94759 1/20 0.52
LDHA P00338 1/20 0.52
ADRB2 P07550 1/20 0.52
FBP1 P09467 1/20 0.52
SRC P12931 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29808596 1.00 NT5E (0.72) NT5EPOLBENPP1P2RY1PDE4D
SCHEMBL17117807 1.00 NT5E (0.72) NT5EPOLBENPP1P2RY1PDE4D
SCHEMBL12932286 0.91 NT5E (0.67) NT5EPOLBENPP1P2RY1PDE4D
SCHEMBL29400356 0.91 NT5E (0.67) NT5EPOLBENPP1P2RY1PDE4D
SCHEMBL345288 0.91 NT5E (0.67) NT5EPOLBENPP1P2RY1PDE4D
SCHEMBL19389361 0.91 NT5E (0.67) NT5EPOLBENPP1P2RY1PDE4D
SCHEMBL4820794 0.91 NT5E (0.67) NT5EPOLBENPP1P2RY1PDE4D
SCHEMBL17117823 0.91 NT5E (0.67) NT5EPOLBENPP1P2RY1PDE4D
SCHEMBL23501737 0.91 NT5E (0.63) NT5EPOLBENPP1P2RY1PDE4D
SCHEMBL285024 0.90 NT5E (0.84) NT5EPOLBENPP1P2RY1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1624059-A2 Method of producing nucleic acid molecules with reduced secondary structure Agilent Technologies, Inc. (US) 2006-02-08 EP claimed
US-20040086880-A1 Method of producing nucleic acid molecules with reduced secondary structure AGILENT TECHNOLOGIES, INC. 2004-05-06 US claimed
US-20230059753-A1 ANTISENSE GUIDE RNA WITH ADDED FUNCTIONAL REGION FOR EDITING TARGET RNA ASTELLAS PHARMA INC. (JP) 2023-02-23 US disclosed
EP-4074825-A1 ANTISENSE GUIDE RNA WITH ADDED FUNCTIONAL REGION FOR EDITING TARGET RNA Astellas Pharma Inc. (JP) 2022-10-19 EP disclosed
CN-114787357-A Antisense guide RNA to which functional region is added for editing target RNA 安斯泰来制药株式会社 2022-07-22 CN disclosed
WO-2021117729-A1 ANTISENSE GUIDE RNA WITH ADDED FUNCTIONAL REGION FOR EDITING TARGET RNA アステラス製薬株式会社 2021-06-17 WO disclosed
US-7682809-B2 Direct ATP release sequencing AGILENT TECHNOLOGIES, INC. (US) 2010-03-23 US disclosed
US-20090181374-A1 DIRECT ATP RELEASE SEQUENCING AGILENT TECHNOLOGIES, INC. 2009-07-16 US disclosed
EP-1624059-A2 Method of producing nucleic acid molecules with reduced secondary structure Agilent Technologies, Inc. (US) 2006-02-08 EP disclosed
US-20040086880-A1 Method of producing nucleic acid molecules with reduced secondary structure AGILENT TECHNOLOGIES, INC. 2004-05-06 US disclosed